Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was
first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The …

Epidermal growth factor receptor is a trans-membrane glycoprotein with an extracellular
epidermal growth factor binding domain and an intracellular tyrosine kinase domain that …

Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study
showed that the addition of cetuximab to first-line chemotherapy significantly improved …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine
kinase, which is overexpressed in many cancers, including non–small-cell lung cancer …

The monoclonal antibodies panitumumab and cetuximab that target the epidermal growth
factor receptor (EGFR) have expanded the range of treatment options for metastatic …

Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …

Somatic mutations in certain tyrosine kinases have emerged as central 'drivers' of specific
cancers and these mutant proteins are proving to be excellent substrates for targeted …

Laboratory studies that led to the development of epidermal growth factor receptor (EGFR)
inhibitors indicated that such inhibitors would be effective when given to patients with …

Purpose Bronchioloalveolar carcinoma (BAC) and adenocarcinomas with BAC features
seem to be increasing in incidence, particularly in younger, never-smoking women …